C-reactive protein downregulates TRAIL expression in human peripheral monocytes via an Egr-1-dependent pathway

Clinical Cancer Research

Volumn 19, Issue 8, 2013, Pages 1949-1959

  Secchiero, Paola ^a   Rimondi, Erika ^a   Di Iasio, Maria Grazia ^a   Agnoletto, Chiara ^a   Melloni, Elisabetta ^a   Volpi, Ilaria ^a   Zauli, Giorgio ^b  

^a UNIVERSITY OF FERRARA   (Italy)

^b INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; C REACTIVE PROTEIN; CD14 ANTIGEN; EARLY GROWTH RESPONSE FACTOR 1; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; POLYMYXIN B; RECOMBINANT PROTEIN; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL STIMULATION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ASSOCIATION; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOSURVEILLANCE; IN VITRO STUDY; MOLECULAR DYNAMICS; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; UPREGULATION;

ANTIGENS, CD14; BLOTTING, WESTERN; C-REACTIVE PROTEIN; CELL LINE, TUMOR; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; EARLY GROWTH RESPONSE PROTEIN 1; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; MONOCYTES; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84877092740     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3027     Document Type: Article

References (57)

1. Secchiero P, Zauli G. TNF-related apoptosis-inducing ligand and the regulation of hematopoiesis. Curr Opin Hematol 2008;15:42-8. (Pubitemid 350191027)
2. Di Pietro R, Zauli G. Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol 2004;201:331-40. (Pubitemid 39453118)
3. Shirley S, Morizot A, Micheau O. Regulating TRAIL receptor-induced cell death at the membrane: a deadly discussion. Recent Pat Anti-cancer Drug Discov 2011;6:311-23.
4. Bisgin A, Kargi A, Yalcin AD, Aydin C, Ekinci D, Savas B, et al. Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer. BMC Cancer 2012;12:58.
5. Tanaka H, Ito T, Kyo T, Kimura A. Treatment with INF alpha in vivo upregulates serum-soluble TNF-related apoptosis inducing ligand (sTRAIL) levels and TRAIL mRNA expressions in neutrophils in chronic myelogenous leukemia patients. Eur J Haematol 2007;78:389-98. (Pubitemid 46558197)
6. Tecchio C, Huber V, Scapini P, Calzetti F, Margotto D, Todeschini G, et al. IFN alpha-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells. Blood 2004;103:3837-44. (Pubitemid 38596303)
7. Kalb ML, Glaser A, Stary G, Koszik F, Stingl G. TRAIL+ Human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod- and IFN-α-mediated antitumor reactivity. J Immunol 2012;188:1583-91.
8. Liabeuf S, Barreto DV, Barreto FC, Chasseraud M, Brazier M, Choukroun G, et al. The circulating soluble TRAIL is a negative marker for inflammation inversely associated with the mortality risk in chronic kidney disease patients. Nephrol Dial Transplant 2010;25:2596-602.
9. Malyszko J, Przybylowski P, Malyszko J, Koc-Zorawska E, Mysliwiec M. Tumor necrosis factor-related apoptosis inducing ligand is a marker of kidney function and inflammation in heart and kidney transplant recipients. Transplant Proc 2011;43:1877-80.
10. Secchiero P, Corallini F, Ceconi C, Parrinello G, Volpato S, Ferrari R, et al. Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction. PLoS ONE 2009;4:e4442.
11. Niessner A, Hohensinner PJ, Rychli K, Neuhold S, Zorn G, Richter B, et al. Prognostic value of apoptosis markers in advanced heart failure patients. Eur Heart J 2009;30:789-96.
12. Mori K, Ikari Y, Jono S, Shioi A, Ishimura E, Emoto M, et al. Association of serum TRAIL level with coronary artery disease. Thromb Res 2010;125:322-5.
13. Secchiero P, Gonelli A, Corallini F, Ceconi C, Ferrari R, Zauli G. Metalloproteinase 2 cleaves in vitro recombinant TRAIL: potential implications for the decreased serum levels of TRAIL after acute myocardial infarction. Atherosclerosis 2010;211:333-6.
14. Secchiero P, Corallini F, Beltrami AP, Ceconi C, Bonasia V, Di Chiara A, et al. An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction. Atherosclerosis 2010;210:274-7.
15. Satoh D, Inami N, Shimazu T, Kajiura T, Yamada K, Iwasaka T, et al. Soluble TRAIL prevents RANTES-dependent restenosis after percutaneous coronary intervention in patientswith coronary artery disease. J Thromb Thrombolysis 2010;29:471-6.
16. Shaker OG, El-Shehaby A, Nabih M. Possible role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand as markers of plaque instability in coronary artery disease. Angiology 2010;61:756-62.
17. Kawano N, Mori K, Emoto M, Lee E, Kobayashi I, Yamazaki Y, et al. Association of serum TRAIL levels with atherosclerosis in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2011;91:316-20.
18. Volpato S, Ferrucci L, Secchiero P, Corallini F, Zuliani G, Fellin R, et al. Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adults. Atherosclerosis 2010;215:452-8.
19. Ikeda T, Hirata S, Fukushima S, Matsunaga Y, Ito T, Uchino M, et al. Dual effects of TRAIL in suppression of autoimmunity: the inhibition of Th1 cells and the promotion of regulatory T cells. J Immunol 2010;185:5259-67.
20. Hofbauer LC, Schoppet M, Christ M, Teichmann J, Lange U. Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis. Rheumatology (Oxford) 2006;45:1218-22. (Pubitemid 44542061)
21. Zai-Xing Y, Yan L, Hao W, Ye Z, Chang L, Ren-Qian Z. Preliminary clinical measurement of the expression of TNF-related apoptosis inducing ligand in patients with ankylosing spondylitis. J Clin Lab Anal 2008;22:138-45. (Pubitemid 351543946)
22. Michowitz Y, Goldstein E, Roth A, Afek A, Abashidze A, Ben Gal Y, et al. The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis. J Am Coll Cardiol 2005;45:1018-24. (Pubitemid 40432432)
23. Watt V, Chamberlain J, Steiner T, Francis S, Crossman D. TRAIL attenuates the development of atherosclerosis in apolipoprotein E deficient mice. Atherosclerosis 2011;215:348-54.
24. Zauli G, Monasta L, Rimondi E, Vecchi Brumatti L, Radillo O, Ronfani L, et al. Circulating TRAIL shows a significant post-partum decline associated to stressful conditions. PLoS ONE 2011;6:e27011.
25. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994;331:417-24. (Pubitemid 24247397)
26. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997;349:462-6. (Pubitemid 27077826)
27. Heikkilä K, Silander K, Salomaa V, Jousilahti P, Koskinen S, Pukkala E, et al. C-reactive protein-associated genetic variants and cancer risk: findings from FINRISK 1992, FINRISK 1997 and Health 2000 studies. Eur J Cancer 2011;47:404-12.
28. Van Hemelrijck M, Holmberg L, Garmo H, Hammar N, Walldius G, Binda E, et al. Association between levels of C-reactive protein and leukocytes and cancer: three repeated measurements in the Swedish AMORIS study. Cancer Epidemiol Biomarkers Prev 2011;20:428-37.
29. Allin KH, Bojesen SE, Johansen JS, Nordestgaard BG. Cancer risk by combined levels of YKL-40 and C-reactive protein in the general population. Br J Cancer 2012;106:199-205.
30. Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci 2011;48:155-70.
31. Zauli G, Corallini F, Bossi F, Fischietti F, Durigotto P, Celeghini C, et al. Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood 2007;110:536-43. (Pubitemid 47105391)
32. Secchiero P, Gonelli A, Mirandola P, Melloni E, Zamai L, Celeghini C, et al. Tumor necrosis factor-related apoptosis-inducing ligand induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway. Blood 2002;100:2421-9.
33. Dasu MR, Devaraj S, Du Clos TW, Jialal I. The biological effects of CRP are not attributable to endotoxin contamination: evidence from TLR4 knockdown human aortic endothelial cells. J Lipid Res 2007;48:509-12. (Pubitemid 46397454)
34. Secchiero P, Gonelli A, Celeghini C, Mirandola P, Guidotti L, Visani G, et al. Activation of the nitric oxide synthase pathway represents a key component of tumor necrosis factor-related apoptosis-inducing ligand-mediated cytotoxicity on hematologic malignancies. Blood 2001;98:2220-8.
35. Secchiero P, Melloni E, di Iasio MG, Tiribelli M, Rimondi E, Corallini F, et al. Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism. Blood 2009;113:4300-8.
36. Campioni D, Secchiero P, Corallini F, Melloni E, Capitani S, Lanza F, et al. Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. Am J Pathol 2005;166:557-63. (Pubitemid 40189051)
37. Milani D, Mazzoni M, Borgatti P, Zauli G, Cantley L, Capitani S. Extracellular human immunode ficiency virus type-1 Tat protein activates phosphatidylinositol 3-kinase in PC12 neuronal cells. J Biol Chem 1996;271:22961-4. (Pubitemid 26314724)
38. Zauli G, Visani G, Bassini A, Caramelli E, Ottaviani E, Bertolaso L, et al. Nuclear translocation of protein kinase C-α and -ζ isoforms in HL-60 cells induced to differentiate along the granulocytic lineage by all-trans retinoic acid (ATRA). Br J Haematol 1996;93:542-50.
39. Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P. Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev 2006;15:381-4. (Pubitemid 43348407)
40. Lee S, Choe JW, Kim HK, Sung J. High-sensitivity C-reactive protein and cancer. J Epidemiol 2011;21:161-8.
41. Gugliotta L, Bagnara GP, Catani L, Gaggioli L, Guarini A, Zauli G, et al. In vivo and in vitro inhibitory effect of a-interferon on megakaryocyte colony growth in essential thrombocythaemia. Br J Haematol 1989;71:177-81. (Pubitemid 19061664)
42. Kiladjian JJ, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood 2011;117:4706-15.
43. Fu M, Zhu X, Zhang J, Liang J, Lin Y, Zhao L, et al. Egr-1 target genes in human endothelial cells identified by microarray analysis. Gene 2003;315:33-41. (Pubitemid 37214895)
44. O'Brien LA, Richardson MA, Mehrbod SF, Berg DT, Gerlitz B, Gupta A, et al. Activated protein C decreases tumor necrosis factor related apoptosis-inducing ligand by an EPCR- independent mechanism involving Egr-1/Erk-1/2 activation. Arterioscler Thromb Vasc Biol 2007;27:2634-41. (Pubitemid 350158916)
45. Coventry BJ, Ashdown ML, Quinn MA, Markovic SN, Yatomi-Clarke SL, Robinson AP. CRP identi fies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool? J Transl Med 2009;7:102.
46. Heikkilä K, Ebrahim S, Lawlor DA. A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health 2007;61:824-33.
47. Heikkilä K, Harris R, Lowe G, Rumley A, Yarnell J, Gallacher J, et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 2009;20:15-26.
48. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7. (Pubitemid 36019639)
49. Finnberg N, Klein-Szanto AJ, El-Deiry WS. TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J Clin Invest 2008;118:111-23.
50. Grosse-Wilde A, Voloshanenko O, Bailey SL, Longton GM, Schaefer U, Csernok AI, et al. TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J Clin Invest 2008;118:100-10.
51. Devaraj S, Jialal I. C-reactive protein polarizes human macrophages to an M1 phenotype and inhibits transformation to the M2 phenotype. Arterioscler Thromb Vasc Biol 2011;31:1397-402.
52. Jialal I, Machha A, Devaraj S. Human C-reactive protein. Small interfering-RNA to protein kinase C-delta reduces the proinflammatory effects of human C reactive protein in biobreeding diabetic rats. Horm Metab Res 2012 Oct 26. [Epub ahead of print].
53. Iyoda T, Zhang F, Sun L, Hao F, Schmitz-Peiffer C, Xu X, et al. Lysophosphatidic acid induces early growth response-1 (Egr-1) protein expression via protein kinase Cd-regulated extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) activation in vascular smooth muscle cells. J Biol Chem 2012;287:22635-42.
54. Devaraj S, Du Clos TW, Jialal I. Binding and internalization of C-reactive protein by Fcgamma receptors on human aortic endothelial cells mediates biological effects. Arterioscler Thromb Vasc Biol 2005;25:1359-63. (Pubitemid 40923352)
55. Saito K, Kihara K. C-reactive protein as a biomarker for urological cancers. Nat Rev Urol 2011;8:659-66.
56. Kinoshita A, Onoda H, Takano K, Imai N, Saeki C, Fushiya N, et al. Pretreatment serum C-reactive protein level predicts poor prognosis in patients with hepatocellular carcinoma. Med Oncol 2012;29:2800-8.
57. Sanjay P, Leaver H, De Figueiredo RS, Ogston S, Kulli C, Polignano FM, et al. Preoperative serum C-reactive protein levels and postoperative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. JOP 2012;13:199-04.